| Identification | Back Directory | [Name]
odiparcil | [CAS]
137215-12-4 | [Synonyms]
odiparcil
SB-424323
Odiparcil - SB 424323
Odiparcil - SB 424323 | GSK 424323
2H-1-Benzopyran-2-one, 4-methyl-7-[(5-thio-β-D-xylopyranosyl)oxy]-
4-methyl-7-[(2R,3R,4S,5S)-3,4,5-trihydroxythian-2-yl]oxychromen-2-one | [Molecular Formula]
C15H16O6S | [MDL Number]
MFCD16038922 | [MOL File]
137215-12-4.mol | [Molecular Weight]
324.35 |
| Chemical Properties | Back Directory | [Boiling point ]
567.4±50.0 °C(Predicted) | [density ]
1.529±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [form ]
Solid | [pka]
12.78±0.70(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Odiparcil (SB-424323) is an orally active beta-d-thioxyloside analog with antithrombotic activity associated with a reduced risk of adverse bleeding events. Odiparcil (SB-424323) is indirect thrombin inhibitor that exerts its anticoagulant effect through activation of antithrombin II (heparin cofactor II) [1][2]. | [storage]
Store at -20°C | [References]
[1] Myers AL, et al. Characterization of total plasma glycosaminoglycan levels in healthy volunteers following oral administration of a novel antithrombotic odiparcil with aspirin or enoxaparin. J Clin Pharmacol. 2008 Oct;48(10):1158-70 DOI:10.1177/0091270008323751
[2] Levy JH, et al. Novel oral anticoagulants: implications in the perioperative setting. Anesthesiology. 2010 Sep;113(3):726-45. DOI:10.1097/ALN.0b013e3181ebdb15 |
|
|